GR3021892T3 - Stabilized vitamin D preparation - Google Patents

Stabilized vitamin D preparation

Info

Publication number
GR3021892T3
GR3021892T3 GR960403313T GR960403313T GR3021892T3 GR 3021892 T3 GR3021892 T3 GR 3021892T3 GR 960403313 T GR960403313 T GR 960403313T GR 960403313 T GR960403313 T GR 960403313T GR 3021892 T3 GR3021892 T3 GR 3021892T3
Authority
GR
Greece
Prior art keywords
active compound
pharmaceutical composition
heat
vitamin
preparation
Prior art date
Application number
GR960403313T
Other languages
Greek (el)
English (en)
Inventor
Hiroki Itoh
Tetsuro Tabata
Jun-Ichi Kikuta
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of GR3021892T3 publication Critical patent/GR3021892T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GR960403313T 1991-04-09 1996-12-04 Stabilized vitamin D preparation GR3021892T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7621091 1991-04-09
JP1909992 1992-02-04

Publications (1)

Publication Number Publication Date
GR3021892T3 true GR3021892T3 (en) 1997-03-31

Family

ID=26355908

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960403313T GR3021892T3 (en) 1991-04-09 1996-12-04 Stabilized vitamin D preparation

Country Status (14)

Country Link
US (1) US5487900A (OSRAM)
EP (1) EP0508756B1 (OSRAM)
JP (1) JPH05279260A (OSRAM)
KR (1) KR100231633B1 (OSRAM)
AT (1) ATE144424T1 (OSRAM)
AU (1) AU649802B2 (OSRAM)
CA (1) CA2065603C (OSRAM)
DE (1) DE69214704T2 (OSRAM)
DK (1) DK0508756T3 (OSRAM)
ES (1) ES2094290T3 (OSRAM)
GR (1) GR3021892T3 (OSRAM)
IE (1) IE75709B1 (OSRAM)
NZ (1) NZ242271A (OSRAM)
TW (1) TW212761B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701264A1 (de) * 1997-01-16 1998-07-23 Kief Lizenz Verwertungsgesells Heilmittel, enthaltend Betasitosterin und/oder Phytosterol/Betasitosteringemische
AU2001278956B2 (en) * 2000-07-18 2007-04-05 Genzyme Corporation Stabilized 1alpha-hydroxy vitamin d
CA2425367A1 (en) * 2000-08-30 2003-04-07 Chugai Seiyaku Kabushiki Kaisha Oct formulations
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンd化合物を含む薬学的組成物
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
CA2924200C (en) * 2005-10-12 2017-09-05 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
WO2007092755A2 (en) 2006-02-03 2007-08-16 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US8329677B2 (en) 2006-06-21 2012-12-11 Cytochroma, Inc. Method of treating and preventing secondary hyperparathyroidism
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
EP3335712B1 (en) 2007-04-25 2025-09-10 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
EP2148661B1 (en) 2007-04-25 2012-12-12 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンd治療法
JP7085105B2 (ja) * 2016-11-10 2022-06-16 日産化学株式会社 ビタミンd3誘導体の製剤
PE20211489A1 (es) 2018-08-31 2021-08-11 Opko Ireland Global Holdings Ltd Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンd3類製剤
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンd▲下3▼類固型製剤
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンd↓3類含有組成物

Also Published As

Publication number Publication date
US5487900A (en) 1996-01-30
KR920019346A (ko) 1992-11-19
ATE144424T1 (de) 1996-11-15
EP0508756B1 (en) 1996-10-23
CA2065603A1 (en) 1992-10-10
IE921126A1 (en) 1992-10-21
JPH05279260A (ja) 1993-10-26
EP0508756A1 (en) 1992-10-14
DE69214704T2 (de) 1997-04-17
KR100231633B1 (ko) 1999-11-15
DE69214704D1 (de) 1996-11-28
ES2094290T3 (es) 1997-01-16
DK0508756T3 (da) 1997-03-24
CA2065603C (en) 2007-04-03
NZ242271A (en) 1993-10-26
AU1480492A (en) 1992-10-15
TW212761B (OSRAM) 1993-09-11
IE75709B1 (en) 1997-09-10
AU649802B2 (en) 1994-06-02

Similar Documents

Publication Publication Date Title
GR3021892T3 (en) Stabilized vitamin D preparation
CA2027592A1 (en) Solid pharmaceutical preparations of active form of vitamin d_ of improved stability
EP0519428A3 (en) Cyclodextrin composition
GR3006177T3 (OSRAM)
AU4740893A (en) Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
EP0197571A3 (en) Novel derivatives of gamma-cyclodextrin
AU3317589A (en) Antacid compositions with prolonged gastric residence time
AU3426795A (en) Solid pharmaceutical composition comprising an excipient capable of binding water
HUT59005A (en) Process for producing transdermal pharmaceutical preparations containing 2-amino-6-(propyl-amino)-4,5,6,7-tetrahydro-benzothiazole
AU1033292A (en) Indole piperazine derivatives and pharmaceutical preparations containing such derivatives
IE873125L (en) Benzimidazole derivatives
EP0598337A3 (en) Medicinal compositions containing a drug, a cross-linked polymer, an oil, and a surfactant.
ATE50980T1 (de) Polymer-stabilisierende verbindungen und diese enthaltende stabilisierte polymerzusammensetzungen.
HUT66234A (en) Process to prepare 4,13-dioxabicyclo(8.2.1)-tridecenon-derivatives and pharmaceutical compositions containing them
AU7043187A (en) Dispersible composition of ceramic solid and a dispersant
CA2063689A1 (en) Ibuprofen lysinate pharmaceutical formulation
GB9112495D0 (en) Improved formulations of acetazolamide
IL102880A0 (en) Hexahydrobenzo(f)quinolinones
AU5140490A (en) Use of mixed micelles
DK0384416T3 (da) Farmaceutisk sammensætning indeholdende hydantoinderivat